FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Poolbeg Pharma PLC Stock AnalysisComprehensive stock analysis for Poolbeg Pharma PLC (POLBF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPOLBF
POLBF
Poolbeg Pharma PLC
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
POLBF
Home🔹Stocks🔹Poolbeg Pharma PLC

Poolbeg Pharma PLC

POLBF•OTC

Poolbeg Pharma PLC

POLBF•OTC
Market cap
$46.61M
Sentiment

Your view on POLBF

Mkt Cap
$46.61M
Sentiment
Your view
POLBF
Poolbeg Pharma PLC
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
POLBF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Poolbeg Pharma PLC

Industry
Biotechnology
Sector
Healthcare
CEO
Jeremy Skillington
Headquarters
Queen Mary BioEnterprises Innovation Ctr, London, GB
Industry
Biotechnology
Sector
Healthcare
CEO
Jeremy Skillington
Headquarters
Queen Mary BioEnterprises Innovation Ctr, London, GB
Description

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News